HOME > REGULATORY

REGULATORY

NHI Price Reduction Method Changed for Aricept, Flolan

January 26, 2012
Rule Review in Similar Drug Re-Pricing Yields 50 Exemptions Based on Competitiveness

January 26, 2012
Correct Dosage, Administration for Lamictal Asked: Pharmaceuticals Safety Info

January 26, 2012
Companies Should Be Required to File Notifications for Package Inserts: Subcommittee

January 26, 2012
HSC Subcommittee Approves Revised Ethical GL for Genomics Research

January 26, 2012
PMDA Considering Review Procedure Policy for IVD Agents Based on FDA Guidance Draft

January 25, 2012
16 APIs Including Aricept, Lyrica to Be Re-Priced for Market Expansion

January 25, 2012
MHLW to Issue Revised Notifications in Preparation for Application to PIC/S

January 25, 2012
Revised Basic Plan Against Cancer to Include Pediatric Cancer Measures

January 24, 2012
Senior Vice Minister Tsuji to Actively Support Creation of 3rd-Party Organization

January 23, 2012
Proposed Amendment of PAL Would Require Submission of Package Inserts: Mr Kikura

January 23, 2012
Huge Drop in Compliance Rate for “Explanations in Writing” in Sales of Class 1 OTC Drugs: MHLW Undercover Survey

January 20, 2012
PMDA to Introduce Direct ADR Reporting System for Patients on Trial Basis

January 20, 2012
Prof. Nakamura of Keio Univ. Sees Orphan Drug Development Strategy as Reason for Revised Re-pricing Policy

January 20, 2012
EMA Initiates Review of Oral MS Treatment Gilenya Following Reports of Heart Problems

January 20, 2012
PAFSC’s Second Committee on Drugs to Review Kyowa Kirin’s ATL Treatment on February 1

January 19, 2012
PMDA to Expand PGx, Biomarker Consultation System

January 19, 2012
MHLW Considering “Partial Introduction” of Medico-Economic Evaluation in FY2014

January 18, 2012
No Serious Concerns Observed for 4 Vaccines: MHLW Study Groups

January 17, 2012
US Industry Opinion Divided on Japan’s Participation in TPP Talks

January 17, 2012

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COLUMN

Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing

By Philip Carrigan

Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…